title: Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia.
abstract: The Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) was examined for its usefulness as a subjective measure of drug-induced parkinsonism and akathisia. Eighty-three subjects were assessed using the LUNSERS, the Simpson-Angus Scale (SAS) and the Barnes Akathisia Rating Scale (BARS), before and after a 6-week treatment with olanzapine. Significant correlations were found between the changes in scores of parkinsonism items of LUNSERS and SAS. The changes in scores of akathisia item (restlessness), extrapyramidal side effects (EPS) subscale and psychic side-effects subscale of LUNSERS were significantly correlated with those of the BARS. 'Shakiness', one item of the EPS subscale of LUNSERS, correctly classified between parkinsonism and non-parkinsonism groups with 81.0% accuracy. A combination of four items included in EPS and psychic side-effect subscales of LUNSERS identified akathisia and non-akathisia groups with 76.2% accuracy. These results suggest that the EPS and psychic side-effect subscales of LUNSERS may be useful in screening for drug-induced parkinsonism and akathisia.
authors.affiliation: Department of Psychiatry, Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Hee-Yeon
authors.initials: HY
authors.lastname: Jung
authors.forename: Jong-Hoon
authors.initials: JH
authors.lastname: Kim
authors.forename: Yong-Min
authors.initials: YM
authors.lastname: Ahn
authors.forename: Seong-Chan
authors.initials: SC
authors.lastname: Kim
authors.forename: Samuel S
authors.initials: SS
authors.lastname: Hwang
authors.forename: Yong-Sik
authors.initials: YS
authors.lastname: Kim
mesh_terms: D000328:Adult; D017109:Akathisia, Drug-Induced / Q000175:diagnosis* / Q000188:drug therapy; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000175:diagnosis / Q000503:physiopathology; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D015897:Comorbidity; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D000077152:Olanzapine; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000175:diagnosis* / Q000188:drug therapy; D010358:Patient Participation; D011569:Psychiatric Status Rating Scales; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D001569:Benzodiazepines; D000077152:Olanzapine